Liminatus Pharma, Inc. has 4 Schedule 13D or 13G filings on record since 2026-02-20. 3 holders' latest filing reports 5% or more of common stock , par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Valetudo Therapeutics LLC | 14.3% | 9,617,954 | SCHEDULE 13D/A, 2026-07-14 | 2026-07-02 |
| Ewon Comfortech Co., Ltd. | 10.9% | 5,500,000 | SCHEDULE 13G/A, 2026-07-06 | 2026-06-24 |
| Samda Biolab Co., Ltd. | 5.1% | 3,426,548 | SCHEDULE 13G, 2026-07-22 | 2026-07-02 |
| Mitchell P. Kopin | 4.99% | 2,065,885 | SCHEDULE 13G, 2026-02-20 | 2026-02-17 |
Purpose of Transaction (Item 4)
Valetudo Therapeutics LLC
The information set forth in Item 3 above is incorporated into this Item 4 by reference. The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. Chris Kim serves as Chief Executive Officer and a director of the Issuer, and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described in this Statement, each of the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons acquired the shares reported herein for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the shares of common stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-20 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-07-06 | Ewon Comfortech Co., Ltd. | 10.9% | SCHEDULE 13G/A |
| 2026-07-14 | Valetudo Therapeutics LLC | 14.3% | SCHEDULE 13D/A |
| 2026-07-22 | Samda Biolab Co., Ltd. | 5.1% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Liminatus Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.